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Global, Regional, and National Cancer Incidence, Mortality,
Years of Life Lost, Years LivedWith Disability, and Disability-
Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
A Systematic Analysis for the Global Burden of Disease Study
Global Burden of Disease Cancer Collaboration
IMPORTANCE Cancer is the second leading cause of death worldwide. Current estimates on
the burden of cancer are needed for cancer control planning.
OBJECTIVE To estimate mortality, incidence, years lived with disability (YLDs), years of life
lost (YLLs), and disability-adjusted life-years (DALYs) for 32 cancers in 195 countries and
territories from 1990 to 2015.
EVIDENCE REVIEW Cancer mortality was estimated using vital registration system data,
cancer registry incidence data (transformed tomortality estimates using separately
estimatedmortality to incidence [MI] ratios), and verbal autopsy data. Cancer incidence was
calculated by dividing mortality estimates through themodeledMI ratios. To calculate cancer
prevalence, MI ratios were used tomodel survival. To calculate YLDs, prevalence estimates
were multiplied by disability weights. The YLLs were estimated bymultiplying age-specific
cancer deaths by the reference life expectancy. DALYs were estimated as the sum of YLDs
and YLLs. A sociodemographic index (SDI) was created for each location based on income per
capita, educational attainment, and fertility. Countries were categorized by SDI quintiles to
summarize results.
FINDINGS In 2015, therewere 17.5million cancer casesworldwide and 8.7million deaths.
Between 2005 and 2015, cancer cases increased by 33%,with population aging contributing
16%, population growth 13%, and changes in age-specific rates contributing 4%. Formen, the
most common cancer globally was prostate cancer (1.6million cases). Tracheal, bronchus, and
lung cancer was the leading cause of cancer deaths andDALYs inmen (1.2million deaths and
25.9million DALYs). For women, themost common cancer was breast cancer (2.4million
cases). Breast cancer was also the leading cause of cancer deaths andDALYs for women
(523000deaths and 15.1million DALYs). Overall, cancer caused 208.3million DALYsworldwide
in 2015 for both sexes combined. Between 2005 and 2015, age-standardized incidence rates
for all cancers combined increased in 174 of 195 countries or territories. Age-standardized
death rates (ASDRs) for all cancers combined decreased within that timeframe in 140 of 195
countries or territories. Countries with an increase in the ASDR due to all cancers were largely
located on the African continent. Of all cancers, deaths between 2005 and 2015 decreased
significantly for Hodgkin lymphoma (−6.1% [95% uncertainty interval (UI), −10.6% to −1.3%]).
The number of deaths also decreased for esophageal cancer, stomach cancer, and chronic
myeloid leukemia, although these results were not statistically significant.
CONCLUSION AND RELEVANCE As part of the epidemiological transition, cancer incidence is
expected to increase in the future, further straining limited health care resources.
Appropriate allocation of resources for cancer prevention, early diagnosis, and curative and
palliative care requires detailed knowledge of the local burden of cancer. The GBD 2015 study
results demonstrate that progress is possible in the war against cancer. However, the major
findings also highlight an unmet need for cancer prevention efforts, including tobacco
control, vaccination, and the promotion of physical activity and a healthy diet.
JAMA Oncol. 2017;3(4):524-548. doi:10.1001/jamaoncol.2016.5688
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I n2015, cancer causedover8.7milliondeaths globally andwasthe second leading cause of death behind cardiovasculardiseases.1 Even though these impressive numbers are testi-
mony that the “war on cancer” has not been won, recent develop-
ments inpersonalizedmedicineandnovel treatmentapproaches like
immunotherapyhave raisedhopeof significantly improving cancer
survival.2-4 These expectations for patients with cancer in high-
income countries contrastwith the challenge ofmaking basic diag-
nostic and treatment options widely available in low-resource
settings.5 Both the equity and affordability of cancer care from in-
dividualandsocietalperspectivesare increasinglybeingquestioned.6
Survival rates between andwithin high-income countries differ for
reasons such as variation in education, access to specialized care,
effective treatment,and insurancestatus.7-9Thefullpotentialofcan-
cerprevention for reducing incidenceandmortality is far frombeing
realized,andeffortsareespecially lagging in low-incomecountries.10
Awareness of this “cancer divide,” with substantially worse out-
comesandahighburden insocioeconomicallydisadvantagedpopu-
lations, has led to a focus on global oncology by the international
health community.4,5,10 This is reflected in the third Sustainable
Development Goal (SDG) to “by 2030, reduce by one-third prema-
ture mortality from non-communicable diseases through preven-
tionandtreatmentandpromotementalhealthandwell-being.”11 Es-
timatesof theburdenof cancer areproducedannually aspartof the
Global Burden ofDisease (GBD) study providing a uniquemeans of
tracking progress in closing this divide. Here, we present results of
the GBD 2015 study for 32 cancer groups covering cancer inci-
dence, mortality, years of life lost (YLLs), years lived with disability
(YLDs), and disability-adjusted life years (DALYs) for 195 countries
or territories from 1990 to 2015 for both sexes across age groups.
Methods
Differences Between GBD 2015 and GBD 2013
Generalmethods forGBD2015andpriorGBDstudieshavebeende-
scribed previously.1,12 Here, we present methods and results spe-
cific to theGBD2015 cancer estimation. Thegeneral framework for
thecancerestimation inGBD2015has remainedsimilar toGBD2013,
exceptions are detailed below.13 The GBD 2015 study is compliant
with thenewly developedGuidelines for Accurate andTransparent
Health Estimates Reporting (GATHER).14 A chart detailing fulfill-
mentofGATHERrequirements is provided ineTable 1 in theSupple-
ment; flowchartsandadetaileddescription foreachestimationstep
arealsoavailable in theeAppendixand in thenumerouseTables and
eFigures in the Supplement. Box 1 includes a list of the figures and
tables in this article. Furtherdetails aboutmethodsanddata sources
areprovided in theeAppendix, eFigures, andeTables in theSupple-
ment.Box2 contains a list of the supplementary figures and tables.
Additional information is available from the authors inWebTables 1
through 3; the web addresses for these items are listed in Box 3.
Hereinafter, citations toWebTablesare for thosegiven inBox3.Data
sources for GBD 2015 are listed in eTable 2 in the Supplement, in-
cluding which new sources were added compared with GBD 2013.
Relevant changes in the estimation strategy since GBD 2013
include the addition of 7 territories (American Samoa, Bermuda,
Greenland, Guam, Northern Mariana Islands, Puerto Rico, and the
US Virgin Islands), which previously were only included in the GBD
regional totals. Results for the United Kingdom are reported for
Northern Ireland,Scotland,Wales,andEngland).ChangestotheGBD
causes include dividing “leukemia” into acute lymphoid leukemia,
chronic lymphoid leukemia,acutemyeloid leukemia,andchronicmy-
eloid leukemia. Methodological updates weremade to themortal-
ity to incidence (MI) ratio estimation, which are described in detail
in the eAppendix in the Supplement.Major updates for theMI ratio
predictions were out-of-sample validation of multiple model
types and selection of 1 model per cancer based on the out-of-
sample root-mean-squared error.
For GBD 2015, a sociodemographic index (SDI) was devel-
oped, which is a summary indicator derived from measures of
income per capita, educational attainment, and fertility. Detailed
methodsdescribingcomputationof theSDIare reportedelsewhere.1
In brief, the SDI weighs each component, which is rescaled be-
tween0 and 1, equally. The composite SDI index is themean of the
3 rescaled components. An SDI of 1.0 can be interpreted as a loca-
tion thathas thehighestobservededucational attainment, thehigh-
est log incomepercapita, and the lowest fertility rate. ForGBD2015,
SDI quintileswereused togroupcountries that are similar basedon
their development status. Locations were grouped into quintiles
basedon their SDI value in 2015.Quintile cutoffswerebasedon the
distribution of geography-years from 1980 to 2015with the excep-
tion of populations smaller than 1million. eFigure 4 and eTable 8 in
the Supplement show the SDI quintile for each country. As for ev-
eryGBD study, the full time series estimated for eachGBDcycle su-
persedes prior GBD studies. For GBD2015, the full time series from
1990to2015wasestimated.We focushereonchangesover the last
decade. Estimates before 2005 aswell as additional results can be
found online (https://vizhub.healthdata.org/gbd-compare/).
Estimation Framework
The initial process in the burden of cancer estimation is themodel-
ing of cancermortality.Oneof theGBDstudy’s principles is to iden-
tify, and ideally use, all available data.15 Data inputs for cancermor-
talityestimationthereforecomefrom2majorpathways: (1)mortality
data and (2) cancer registry incidence data transformed tomortal-
ity estimates. Mortality data from vital registration systems, verbal
autopsies, andother sources like disease surveillance recordswere
processed and added to a cause-of-death database. Methods and
data sources have been described in detail previously.1
Key Points
Question What is the burden of cancer between 1990 and 2015 at
the global, regional, and national level measured in incidence,
mortality, years lived with disability, years of life lost, and
disability-adjusted life-years (DALYs) by sex and age?
Findings Using the Global Burden of Disease (GBD) methodology,
we estimated that in 2015, there were 17.5 million cancer cases, 8.7
million deaths, and 208.3 million DALYs. Between 2005 and 2015,
incident cancer cases increased by 33%, of which 12.6%were due
to population growth, 16.4% due to an aging population, and 4.1 %
due to increasing age-specific incidence rates.
Meaning Cancer control, which requires a detailed understanding
of the cancer burden as provided in the GBD, is of utmost
importance given the rise in cancer incidence due to
epidemiological and demographic transition.
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Tomaximize data availability and take advantage of cancer reg-
istrydata incountrieswithscarcemortalitydata, incidencedata from
cancerregistriesweretransformedtomortalityestimatesthroughthe
useof separatelyestimatedMI ratios.Modelingof theMI ratios isde-
scribed indetail in the eAppendix in the Supplement. In brief, the es-
timation followeda3-stepapproach, thecreationof logit randomef-
fect models, spatiotemporal smoothing, and Gaussian process
regression. A final model was selected based on out-of-sample vali-
dation.Updatedcancer registrydata forGBD2015wasobtainedfrom
the GBD collaborator network or downloaded from publically avail-
able sources. All data sources used forMI ratio estimation, aswell as
thoseusedfor incidencedatatransformedtomortalityestimates,are
listed in the eAppendix and eTable 2 in the Supplement.
For cancer estimation, 333 513 site-years were used from vital
registration systems, 785 site-years from verbal autopsy, 619 site
years fromsurveillancedata, and69013 site years fromcancer reg-
istrydata. Thenumberof site-yearsusedbysource typeandbycan-
cercanbe found ineTable3 in theSupplement.All datasourceswere
extracted at the most detailed cause- and age-specific level and
mapped to the GBD cause list. Codes from the International Classi-
fication of Diseases, Ninth Revision (ICD-9), and International Sta-
tistical ClassificationofDiseasesandRelatedHealthProblems, Tenth
Revision (ICD-10), for each GBD cancer group as well as a descrip-
tion of data processing steps can be found in the eAppendix in the
Supplement. The 32 cancer groups, together referred to as the “all
cancer”group,encompassallmalignantneoplasmsasdefined in the
ICD-10 except for nonmelanoma skin cancer (NMSC, ICD-10 code
C44) andKaposi sarcoma (ICD-10 codeC46).AlthoughNMSC is the
most common cancer in many populations, most cancer registries
donot includeNMSC,whichnecessitatesdifferentestimationmeth-
ods from the cancers presented here.16 Deaths due to Kaposi sar-
comaarenot separately includedbecause thesewere attributed to
human immunodeficiency virus/AIDS in the GBD study.
The combined data on individual causes of deathwere used as
input for the Cause of Death Ensemble model (CODEm).17 Covari-
ates used for each cancer are listed in the eAppendix in the Supple-
ment. Individual causemortality estimates fromCODEmwere con-
strained to fit independentlymodeled, all-causemortalityestimates
using the tool CodCorrect.1We calculatedYLLs bymultiplying each
deathwith the life expectancy for that age taken from a normative
life table; life expectancy at birthwas 86.5 years, which is based on
the lowest observed death rate in each 5-year age group in popula-
tions over 5 million.1
Final mortality estimates were transformed into incidence es-
timatesusingmodeledMI ratios.Uncertainty fromthemortality es-
timation and from the MI ratio estimation was propagated to the
incidence estimates. Ten-year cancer prevalence was modeled by
estimating cancer survival using an MI ratio–based scaling factor,
which takes into account location, year, and sex (see the eAppen-
dix in the Supplement for details). This factorwas used to scale the
incidence cohort between a theoretical best-case and a theoretical
worst-case survival. The absolute survival estimates allowed calcu-
lation of 10-year prevalence for each incidence cohort.
Total prevalence was divided into 4 sequelae reflecting vary-
ingdegreesofdisabilityduring the cancer continuum: (1) diagnosis/
treatment, (2) remission, (3)metastatic/disseminated, and (4) ter-
minal phase. Duration of the 4 prevalence phases by cancer can be
found in eTable 13 in the Supplement. Since data sources including
stage distribution and treatment approaches are not available for
most countries, the simplifying assumption of a constant duration
of the diagnosis and treatment, metastatic/disseminated, and ter-
minal phase for all ages, over time, and all countries wasmade. Af-
terdividing totalprevalence into these3sequelae,weattributed the
remaining prevalence to the remission phase.
To calculate YLDs, the prevalence for each sequela was multi-
pliedwithadisabilityweight.Additional disabilitywasestimated for
procedures andprocedure-relatedmorbidities associatedwith the
treatment of breast, larynx, colorectal, bladder, and prostate can-
cer (mastectomy, laryngectomy, stoma, urinary incontinence, and
impotence) under the assumption that these are major disabling
sequelae after cancer treatment. Disability weights used for the
different sequelae as well as methods to determine disability
prevalence for these cancer-related outcomes can be found in the
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We calculated 2 scenarios to analyze the contribution of
population aging, population growth, and changes in the age-
specific incidence rateson theabsolute changeof cancer incidence.
In the first scenario, the age structure, sex structure, and the age-
specific rates from2005were applied to the total populationof the
year2015.Thedifferencebetweenthetotalnumberofcases in2005
andthehypothetical scenariowereattributed topopulationgrowth.
In thesecondhypothetical scenario, theage-specific rates from2005
wereapplied to theagestructure, sex structure, andpopulation size
of 2015.Differencesbetween the secondhypothetical scenario and
the first hypothetical scenario were attributed to population aging.
Differences between the total number of cases in 2015 and the sec-
ond hypothetical scenario were attributed to changes in the age-
specific rates.
Inthispublication,allratesarereportedper100000person-years.
TheGBDworldpopulationstandardwasusedforthecalculationofage-
standardizedweights.18Wereport95%uncertainty intervals (UIs) for
all estimates (listed in parentheses after point estimates).
Results
Global Incidence, Mortality, and DALYs
In2015, therewere 17.5million incident cancer casesworldwideand
8.7millioncancerdeaths, asdetailed inTable 1. Cancercaused208.3
millionDALYs in 2015, ofwhich96%came fromYLLs and4%came
from YLDs (Web Table 3). At the global level, the odds of develop-
ing cancer during a lifetime (age 0-79 years) differed between the
sexes: they were 1 in 3 for men and 1 in 4 for women (eTable 16 in
the Supplement). These odds differ substantially among SDI cat-
egories. In the lowestSDIquintile, theoddsofdevelopingcancer for
men agedbetween0and 79 yearswere 1 in 6,whereas in the high-
est SDI quintile, 1 in 2men developed cancer. Forwomen, the odds
of developing cancer was 1 in 5 in the lowest SDI quintile and 1 in 3
in the highest quintile.
In2015,prostatecancer,TBL(tracheal,bronchus,and lung)can-
cer, andcolorectal cancerwere themost common incident (95%UI)
cancers inmen—accounting for42%ofall cancercasesamongmen—
with 1.6 million (1.3-2.2 million), 1.4 million (1.3-1.5 million), and
920000 (878000-965 000) cases, respectively (Table 1). The
most commoncausesof cancerdeaths formenwereTBL, liver, and
stomach cancer with 1.21 (1.16-1.25) million, 577 000 (524 000-
622000), and 535000 (516000-556000) deaths, respectively.
The leadingcauses for cancerDALYs in2015 formenwereTBL, liver,
and stomach cancer, with 25.9million (25.0-27.0million), 15.4mil-
lion (14.0-16.7 million), and 11.7 million (11.2-12.2 million), respec-
tively. Forwomen in2015, themost common incident cancerswere
breast, colorectal, and TBL cancer, with 2.4 million (2.2-2.5 mil-
lion), 733 000 (702 000-767 000), and 640 000 (602 000-
690000), respectively. These cancers were responsible for 46%
of all incident cases among women. The leading causes of cancer
deathswerebreast, TBL, andcolorectal cancer, 523000(492000-
543000), 517 000 (497000-538000), and 376000 (363000-
391 000) deaths, respectively. Breast, TBL, and colorectal cancer
were also the leading causes for female cancer DALYs in 2015, with
15.1million (14.2-15.9million), 10.5million (10.1-11.0million), and 7.2
million (7.0-7.5million), respectively.
Figure 1 shows thepatternof cancer incidenceandmortalityby
age group. For childhood cancers (age 0-14 years), the most com-
mon were leukemia, other neoplasms (see eTables 4 and 5 in the
Supplement for ICDcodes includedunder “otherneoplasms”), non-
Hodgkin lymphoma (NHL), and brain and nervous system cancers
(Figure 1A). Leukemia, otherneoplasms, andbrain andnervous sys-
tem cancers were also the leading contributors to childhood can-
cer deaths (Figure 1B). For adolescents andyoungadults (age 15-39
years) themostcommoncancersat theglobal levelwerebreast can-
cer, cervical cancer, and other neoplasms. Themain causes of can-
cer deaths for this age groupwere leukemia, other neoplasms, and
liver cancer. For thepopulationolder than39years, thecancers con-
tributing themost incidentcaseswereTBL,breast,prostate, andco-
lorectal cancer,while themain contributors to cancer deaths in this
age group were TBL, stomach, and colorectal cancer.
Between 2005 and 2015, age-standardized incidence rates
(ASIRs) for all cancers combined increased in 174 of 195 countries
or territories (Figure 2). Chinawas a notable exception, with a 12%
decrease in cancer incidence. In contrast, age-standardized death
rates (ASDR) for all cancers combined decreased within that time-
frame in 140 of 195 countries or territories, as shown in Figure 3,
whichalsoshowsthatcountrieswithan increase inASDRwere largely
located on the African continent.
Thenumber (95%UI)of incident cases increased inall SDIquin-
tilesbetween2005and2015 fornearly all cancers; exceptionswere
esophageal cancer inmiddle and high-middle SDI countries,where
incidence fell by 9% (−24.3% to 8.3%) and 4% (−17.7% to 14.0%),
respectively, andcervical cancer inmiddle,high-middle, andhighSDI
countries, with a 5% (−19.6% to 12.3%), 5% (−14.3 to 6.2), and 2%
(−7.4%to2.9%)decrease, respectively (WebTable1).However, these
decreases were not statistically significant. The largest increase in
cancer incident cases between 2005 and 2015 occurred in low SDI
countries, with a 50% increase, of which population growth con-
tributed33%,changingage-specific incidence rates 13%,andchang-
ingagestructure4%(eTable 15 in theSupplement).Thesecond larg-
est increase occurred in the low-middle SDI quintile, with a 40%
increase, followedbyhighSDI countries,with a36% increase, high-
middle SDI countries, with a 28% increase, and middle SDI coun-
tries, with a 27% increase (eTable 15 in the Supplement).
Global Top 10 Cancers in 2015
The top 10 cancers were ranked highest (top) number of incident
cases (Figure 4).
1. Breast Cancer
Breast cancer was the most common cancer overall, with an esti-
mated 2.4 million (95% UI, 2.3-2.5 million) incident cases in 2015.
Thevastmajority occurred inwomen,with2.4million (95%UI, 2.2-
2.5million)casesvs44000(95%UI,40000-49000)cases inmen
Box 3.Web Table Addresses
Web Table 1. Incidence (absolute numbers and rates) by sex, 2005,
2015 (ja.ma/healthdataorg_webtable1_incidence)
Web Table 2. Mortality (absolute numbers and rates) by sex, 2005,
2015 (ja.ma/healthdataorg_webtable2_mortality)
Web Table 3. DALYs (absolute numbers and rates) by sex, 2005,
2015 (ja.ma/healthdataorg_webtable3_DALYs)
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(Table 1).Breastcancerwasthe leadingcauseofcancer inall SDIquin-
tiles except for the high and high-middle SDI quintiles where it was
thesecondmostcommoncancer (Figure4). Itwasthecauseofdeath
for523000(95%UI,492000-543000)womenand10000(95%
UI, 9000-11 000) men, making it the fifth leading cause of cancer
deaths for both sexes in 2015 at the global and the low SDI coun-
tries, the fourth leading cause in high SDI countries, the sixth lead-
ingcause inhigh-middleandmiddleSDIcountries,andthethird lead-
ingcause inthe low-middleSDIquintile (Figure5).Forwomen,breast
cancerwas the leading cause of death in 2015 (Table 1). Breast can-
cer caused 15.4 million (95% UI, 14.4-16.2 million) DALYs for both
sexes, ofwhich 88%came fromYLLs, and 12% fromYLDs (eFigure
13 in the Supplement). One in 14 women and 1 in 603 men devel-
opedbreast cancerbetweenbirthandage79years (eTable 16 in the
Supplement) at the global level. For women, the odds of develop-
ing breast cancer were the highest in high SDI countries, with 1 in 9
women developing breast cancer, compared with the lowest odds
of 1 in 20women inmiddle SDI countries developing breast cancer
between age 0 and 79 years.
For women (per 100000 person-years) in 2015, ASIRs (95%
UIs) and ASDRs (95% UIs) were the lowest in East Asia: ASIR 35.8
(27.5-45.4), ASDR 8.2 (6.9-9.3); South Asia: ASIR 44.4 (37.1-52.3),
ASDR 11.9 (10.6-12.9); and Andean Latin America: ASIR 47.2 (39.6-
54.6), ASDR 10.5 (9.1-12) (Web Tables 1 and 2). Theywere the high-
est in high-income North America: ASIR 124.8 (115.9-145.4), ASDR
19.9 (18.9-23.2);WesternEurope:ASIR 124.7 (116.3-138.3),ASDR21.8
(20.5-23.6);andAustralasia:ASIR123.7 (112.5-137.9),ASDR19.8(18.3-
21.4).
Figure 1. Age-Specific Global Contributions of Cancer Types to Total Cancer Incidence andMortality For Both Sexes, 2015
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Breast cancer was themost common cancer for women in 183
countriesor territoriesandthemostcommoncauseofcancerdeaths
in women in 115 countries or territories (eFigures 10 and 12 in the
Supplement).
Between2005and2015,breast cancer remained the fifth lead-
ingcauseofglobal cancerYLLs, as shown inFigure6. If global popu-
lationsizeandagestructurehadremainedstablebetween2005and
2015, the change in age-specific incidence ratesbetween2005and
2015wouldhaveresulted ina15%increase in incidentcases(Table2).
Overall incident cases increased by 43% because of population
growth (contributing an additional 13%) and aging (contributing
15%).TheASIR (95%UI) forwomen(per 100000person-years)be-
tween 2005 and 2015 increased by 12% (95% UI, 4.3%-19.5%) at
the global level from 58.5 (55.7-61.9) to 65.5 (61.7-68.8). The larg-
est increaseoccurred in lowSDIcountries,witha26%increase, from
52.8 (43.8-70.2) to66.4 (51.3-88.2). ASIR at theglobal level and for
all SDI quintiles increased since 1990 (Figure 7). Age-standardized
DALY rates (95% UI) for women between 2005 and 2015 de-
creased by 6% (−12.1% to −1.0%) at the global level, with the larg-
est decrease of 10% (−17.9% to −3.3%) in high-middle SDI coun-
tries and the largest increase in low SDI countries of 10% (−12.5%
to 38.5%), which was not statistically significant (Web Table 3).
2. Tracheal, Bronchus, and Lung Cancer
In 2015, there were 2 million (95% UI, 1.9-2.1 million) incident cases
of TBL cancer and 1.7 million (95% UI, 1.67-1.77 million) deaths. Tra-
cheal, bronchus, and lung cancer caused 36.4million (95%UI, 35.4-
37.6 million) DALYs in 2015, of which 99% came from YLLs and 1%
from YLDs (eFigure 13 in the Supplement). Men were more likely to
developTBLcancer thanwomen,with 1 in 18menand1 in45women
developing TBL cancer betweenbirth and age 79 years (eTable 16 in
theSupplement).Theoddswerethehighest inhighSDIcountries,with
1 in 13menand1 in27womendevelopingTBLcancer. In lowSDIcoun-
tries the oddswere substantially lower, with 1 in 70men and 1 in 199
womendevelopingTBLcancerbetweenbirthandage79years.Over-
all, TBLcancerhad the secondhighest absolute incidenceglobally as
well as inmiddle and low-middle SDI countries; TBLwas the leading
causeofcancer inhigh-middleSDIcountriesandrankedfourth inhigh
SDIcountriesandtenth in lowSDIcountries (Figure4). Itwasthemost
commoncauseof cancerdeathsbyabsolute casesglobally aswell as
in all SDI quintiles except for countries in the low SDI group, where
TBL cancer ranked seventh (Figure 5).
ASIRsandASDRs (95%UI) (per 100000person-years) formen
were the lowest in Eastern Sub-Saharan Africa: ASIR 8.6 (6.9-10.7),
ASDR 10.3 (8.1-13.0); Central Sub-Saharan Africa: ASIR 11.7 (7.8-17.0),
ASDR14.2(9.3-20.9);andWesternSub-SaharanAfrica:ASIR12.8(10.7-
16.5), ASDR 13.9 (11.4-17.4). They were the highest in men in high-
income North America: ASIR 70.9 (66.3-75.7), ASDR 50.3 (48.3-
52.3);CentralEurope:ASIR70.5(66.5-75.0),ASDR61(58.6-63.1);and
high-income Asia Pacific: ASIR 67.5 (62.8-72.4), ASDR 42.1 (40.5-
43.8). For women in 2015, incidence rates were the lowest in East-
ern Sub-Saharan Africa: ASIR 2.7 (2.0-3.6), ASDR 3.2 (2.3-4.2);
Figure 2. Relative Changes in Age-Standardized Cancer Incidence Rates in Both Sexes for All Cancers in 195 Countries or Territories From2005 to 2015
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COM, Comoros; DMA, Dominica; E Med: Eastern Mediterranean; FJI, Fiji;
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sarcoma; LCA, Saint Lucia; MDV, Maldives; MLT, Malta; MUS, Mauritius;
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SLB, Solomon Islands; SYC, Seychelles; TLS, Timor-Leste; TON, Tonga;
TTO, Trinidad and Tobago; VCT, Saint Vincent and the Grenadines;
VUT, Vanuatu; W Africa, West Africa; WSM, Samoa.
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WesternSub-SaharanAfrica:ASIR5.2(3.9-7.5),ASDR5.6(4.3-8.1);and
SouthAsia:ASIR5.3(4.5-6.3),ASDR5.5(5.1-5.9). Incidencerateswere
thehighest inhigh-incomeNorthAmerica:ASIR51.7(48.2-55.5),ASDR
32.9 (31.6-34.1); Australasia: ASIR 28.9 (25.7-32.4), ASDR 19.3 (18.0-
20.8); andhigh-incomeAsiaPacific:ASIR25.4 (23.5-27.5),ASDR12.6
(12.0-13.2). (Web Tables 1 and 2). Tracheal, bronchus, and lung can-
cerwas the cause of themost incident cases formen in 38 countries
andthemostcommoncause forcancerdeaths in 113countriesor ter-
ritories (eFigures 9 and 11 in the Supplement). For women, TBL can-
cerwasthemostcommoncauseofcancerdeaths in20countriesand
territories (eFigure 12 in the Supplement).
Between 2005 and 2015, TBL cancer cases increased by 29%
(95%UI, 21.5%-37.0%) (WebTable 1). Populationgrowthalonecon-
tributed 13%. Aging of the population contributed 18%of the total
increase. This increase was partially offset by a decrease in age-
specific rates, which would have led to a 2% decrease in incidence
if the age structure and population size had remained constant be-
tween 2005 and 2015. Figure 8 shows slightly decreasing ASIR at
the global level formen and increasing trends for women between
1990and2015. This trendwasmuchmorepronounced for thehigh
SDI quintile.
3. Colon and Rectum Cancer
In2015, therewere 1.7million (95%UI, 1.6-1.7million) incident cases
of colon and rectum cancer, and it caused 832 000 (95% UI,
812000-855000)deaths(Table1).Colonandrectumcancercaused
17 million (95% UI, 16.6-17.5 million) DALYs in 2015 of which 96%
came fromYLLs and4%came fromYLDs (eFigure 13 in the Supple-
ment). Theoddsof developing colonand rectumcancerbefore age
79 years at the global levelwas higher formen than forwomen (1 in
28men, 1 in 43women, eTable 16 in the Supplement). The highest
oddswere in thehighSDIquintile,with 1 in 14menand1 in23women
developing colorectal cancer comparedwith 1 in94menand 1 in 112
women in the low SDI quintile. Globally, and for high SDI countries,
colon and rectumcancer ranked third for cancer incidence and sec-
ond for cancerdeaths in2015as shown inFigures4and5.Colonand
rectum cancer incidence ranked lowest in low SDI countries as the
eighthmostcommoncancerandwas thesixth leadingcause forcan-
cer mortality.
As can be seen inWeb Tables 1 and 2, in 2015 ASIRs andASDRs
(95% UI) per 100000 person-years for men were the lowest in
South Asia: ASIR 8.2 (6.9-9.5), ASDR 6.3 (5.8-6.8); Central Sub-
Saharan Africa: ASIR 8.7 (5.9-12.9), ASDR 9.5 (6.4-14.1); and West-
ernSub-SaharanAfrica:ASIR9.0 (7.4-12.2),ASDR8.7 (7.2-11.1). Rates
were highest in Australasia: ASIR 86.4 (76.1-98.5), ASDR21.3 (19.9-
22.9); high-income Asia Pacific: ASIR 78.7 (74.3-83.4), ASDR 21.8
(21.1-22.6); andWestern Europe: ASIR 60.0 (56.7-63.3), ASDR 21.9
(20.9-22.8). For women, rates in 2015 were the lowest in Western
Sub-SaharanAfrica:ASIR7.1 (5.6-9.8),ASDR7.1 (5.6-10.1); SouthAsia:
ASIR7.1 (6.0-8.4),ASDR5.7 (5.3-6.2);andCentralSub-SaharanAfrica:
ASIR8.3 (5.3-12.3),ASDR9.1 (5.5-14.0).Theywere thehighest inAus-
tralasia:ASIR64.9(56.6-74.5),ASDR15.3(14.1-16.7);high-incomeAsia
Figure 3. Relative Changes in Age-Standardized CancerMortality Rates in Both Sexes for All Cancers in 195 Countries or Territories From 2005 to 2015
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Pacific: ASIR 43.7 (40.9-46.8), ASDR 12.7 (12.2-13.3); and high-
income North America: ASIR 42.8 (39.6-46.4), ASDR 13.4 (12.8-
14.0). Colon and rectum cancerwas the cancer with the highest in-
cidence in2015 formen in6countries (eFigure9 in theSupplement).
Figure 4. Cancers Ranked by Number of Incident Cases in Both Sexes, Global, by Region, by Sociodemographic Index (SDI), and in the 50Most
Populous Countries, 2015
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Forwomen, colon and rectumcancerwas themost common cause
of cancer deaths in 5 countries (eFigure 12 in the Supplement).
Colonand rectumcancerhas remained the fourth leading cause
for cancer YLLs between 2005 and 2015 (Figure 6). As summarized
Figure 5. Cancers Ranked by Number of Deaths in Both Sexes, Global, by Region, by Sociodemographic Index (SDI), and in the 50Most Populous
Countries, 2015
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inTable2,between2005and2015, incidence (95%UI) increasedby
37%(32.1%-41.0%)from1.2million(1.19-1.24million)to1.7million(1.6-
1.7million) cases. Most of this increase can be explained by an aging
andgrowingpopulation,however,evenwiththesamepopulationsize
and age structure, colon and rectum cancer cases would have in-
creased by 5% between 2005 and 2015 reflecting a change in age-
specific incidence rates.
Figure9showssimilar trends inASIRsbetweenmenandwomen
for all levels of SDI except for the high-middle SDI quintile, where
trendsaredecreasing inwomenbut increasing inmen.Ascanbeseen
inWebTable 1, ASIRs (95%UIs) have increasedby 7% (1.8%-11.6%)
between 2005 and 2015 for men but have remained stable for
women at the global level: −0.2% (−4.3% to 4.4%). The largest in-
crease occurred in low-middle SDI countries at 25% (10.3%-
40.2%) for men and 13% (0.7%-27.4%) for women.
Between2005and2015, age-standardizedDALYrates forboth
sexes decreased by 8% (−10.2% to −6.2%) at the global level, with
the largest decrease in high-SDI countries of 11% (−13.6% to −9.1%)
and the largest (nonsignificant) increase in the low SDI quintile of
9% (−6.0% to 27.8%) (Web Table 3).
4. Prostate Cancer
In2015, therewere 1.6million (95%UI, 1.3-2.2million) incidentcases
of prostate cancer and 366 000 (95% UI, 303 000-460000)
deaths. Prostate cancer caused6.3million (95%UI, 5.2-7.9million)
DALYs globally in 2015, with 82% coming from YLLs and 18% from
Figure 6. Cancers Ranked Globally and for Both Sexes by Absolute Years of Life Lost (YLLs)
1 Tracheal, bronchus, and lung cancer 1Tracheal, bronchus, and lung cancer
2 2Liver cancerLiver cancer
3 Stomach cancer 3Stomach cancer
4 4Colon and rectum cancerColon and rectum cancer
5 Breast cancer 5Breast cancer
6 6LeukemiaLeukemia
7 Esophageal cancer 7Esophageal cancer
8 8Pancreatic cancerBrain and nervous system cancer
9 Cervical cancer 9Brain and nervous system cancer
10 10Cervical cancerPancreatic cancer
11 Non-Hodgkin lymphoma 11Non-Hodgkin lymphoma
12 12Prostate cancerAcute lymphoid leukemia
13 Acute myeloid leukemia 13Acute lymphoid leukemia
14 14Acute myeloid leukemiaProstate cancer
15 Ovarian cancer 15Ovarian cancer
16 16Lip and oral cavity cancer Lip and oral cavity cancer 
17 17Bladder cancer
18 Kidney cancer 18Bladder cancer
19 19Gallbladder and biliary tract cancerGallbladder and biliary tract cancer
20 Larynx cancer 20Larynx cancer
21 21Multiple myelomaUterine cancer
22 Nasopharynx cancer 22Uterine cancer
23 23Nasopharynx cancerMultiple myeloma
24 Other pharynx cancer 24Other pharynx cancer
25 25Malignant skin melanomaMalignant skin melanoma
26 Chronic lymphoid leukemia 26Chronic lymphoid leukemia
14.3 (10.8 to 18.9)
4.6 (−1.6 to 15.4)
−6.9 (−10.2 to −3.7)
17.4 (14.8 to 20.2)
17.2 (9.3 to 24.3)
6.2 (2.5 to 9.9)
−7.8 (−12.7 to −2.3)
26.1 (23.2 to 29.0)
13.0 (4.8 to 20.8)
2.3 (−4.4 to 10.8)
22.7 (10.3 to 30.4)
25.9 (22.0 to 29.9)
3.8 (−2.1 to 9.6)
13.1 (7.8 to 18.0)
18.0 (13.1 to 22.9)
27.5 (23.4 to 32.2)
24.6 (19.7 to 29.0)
17.9 (14.3 to 21.6)
6.7 (2.1 to 11.4)
9.6 (6.3 to 13.2)
27.9 (22.8 to 32.5)
4.5 (−2.2 to 12.6)
5.5 (−2.5 to 12.0)
20.4 (14.7 to 25.9)
19.1 (12.6 to 23.9)
5.5 (−0.1 to 11.1)
−9.4 (−13.3 to −4.9)
−12.1 (−16.2 to −7.9)
28.6 (24.1 to 33.2)
18.7 (8.3 to 24.8)
5.0 (−1.9 to 11.19)
−11.5 (−14.2 to −8.0)
−16.9 (−21.6 to −8.8)
−27.3 (−29.8 to −24.7)
−8.9 (−10.8 to −6.8)
−7.5 (−13.5 to −2.2)
−8.0 (−11.1 to −4.9)
−28.7 (−32.5 to −24.5)
−2.8 (−4.9 to −0.6)
−5.3 (−11.8 to 1.1)
−18.6 (−24.0 to −12.0)
0.3 (−9.4 to 6.0)
−4.2 (−7.1 to −1.3)
−6.4 (−11.5 to −1.3)
−3.1 (−7.4 to 0.9)
−7.5 (−11.3 to −3.9)
−0.2 (−3.5 to 3.4)
−1.5 (−4.9 to 2.0)
−17.6 (−21.2 to −13.9)
−15.1 (−17.6 to −12.3)
−9.6 (−12.3 to −6.8)
−1.0 (−4.8 to 2.3)
−18.8 (−24.0 to −12.6)
14.6 (−20.9 to −9.4)
−6.7 (−11.0 to −2.4)
−5.0 (−10.1 to −1.2)
−15.4 (−19.7 to −11.1)
−25.4 (−28.5 to −21.9)
−25.7 (−29.3 to −22.1)
1.9 (−1.6 to 5.3)
−7.1 (−15.0 to −2.3)
−8.6 (−14.7 to −3.4)
27 Chronic myeloid leukemia 27Chronic myeloid leukemia
28 Hodgkin lymphoma 28Hodgkin lymphoma
29 Thyroid cancer 29Mesothelioma
30 Mesothelioma 30Thyroid cancer
31 Testicular cancer 31Testicular cancer
Kidney cancer 
Rank Rank Cancer  Cancer
Change in A-YLLs,
% (95% CI)
Change in AS–YLL
Rate, % (95% CI) 
2005 2015
Rank increased No change Rank decreased
Illustrated data include the percentage change in absolute YLLs (A-YLLs) and
the percentage change in the age-standardized YLL (AS-YLL) rate between
2005 and 2015;. The “other cancers” group is not included in these data
because it contains multiple different types of cancers. Solid lines connecting
the 2005 and 2015 charts indicate increased or unchanged rank for the
connected cancers; dotted lines indicate decreased rank.
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YLDs (eFigure 13 in the Supplement). The odds of developing pros-
tate cancerbetweenages0 to79yearswas 1 in 14at theglobal level
and ranged from 1 in 47 men for low-middle SDI countries to 1 in 6
men in high SDI countries (eTable 16 in the Supplement).
Figure 7. Trends in Age-Standardized Incidence Rates for Breast Cancer, 1990-2015
Global
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Figure 8. Trends in Age-Standardized Incidence Rates for Tracheal, Bronchus, and Lung Cancer, 1990-2015
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Figure 9. Trends in Age-Standardized Incidence Rates for Colon and Rectum Cancer, 1990-2015
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ASIRs and ASDRs (95% UIs) for prostate cancer in 2015 were
the lowest in SouthAsia: ASIR 11.5 (8.1-17.5), ASDR7.2 (5.4-9.1); East
Asia: ASIR 12.1 (8.6-16.9), ASDR 6.6 (5.0-8.5); and Central Sub-
SaharanAfrica:ASIR20.5 (12.7-29.8),ASDR17.6 (11.1-25.1). Theywere
thehighest inAustralasia:ASIR243.9 (162.6-336.6),ASDR24.1 (17.3-
31.8); high-incomeNorthAmerica: ASIR 158.6 (126.0-250.6), ASDR
17.7 (14.4-27.4), andWesternEurope:ASIR 151.0 (114.2-230.5),ASDR
20.8 (16.3-30.4) (Web Tables 1 and 2).
In 2015, prostate cancer was the cancer with the highest inci-
dence formen in 103 countries or territories, and the leading cause
of cancer deaths for men in 29 countries (eFigures 9 and 11 in the
Supplement).
Prostate cancer ranked 14th in 2005and 12th in 2015 for cancer
YLLs (Figure 6) with an increase of 26% (95%UI, 22.0%-29.9%) in
absoluteYLLsbetween2005and2015.Assummarized inTable2, the
increasing incidencerates, togetherwithanagingandgrowingpopu-
lation,have ledtoa66%increase inprostatecancercasessince2005
(974000 in2005, 1.6million in 2015). Thirty-four percent of this in-
crease can be attributed to a change in the age-specific rates.
ProstatecancerASIRs (95%UIs) formenwerethe lowest in low-
middle SDI countries (17.6; 12.9-22.5) and the highest in high SDI
countries (123.6; 92.6-181.7). ASIRs have been increasing in all SDI
quintiles between 1990 and 2015, with the largest increase in the
high-SDI countries (Figure 10). Age-standardizedDALY rates (95%
UIs) in men were the highest in low SDI countries (368.2; 249.3-
476.1) and the second highest in high SDI countries (302.4; 231.0-
432.0) (Web Table 3).
5. Stomach Cancer
In2015, therewere 1.3million (1.2-1.4million) incidentcasesof stom-
achcancerand819000(95%UI,795000-844000)deathsworld-
wide. Stomach cancer caused 17.4million (95%UI, 16.9-18million)
DALYs in 2015 with 98% coming from YLLs and 2% coming from
YLDs (eFigure 13 in the Supplement). One in 27 men and 1 in 68
women develop stomach cancer before age 79 years. The highest
odds formenoccurred inmiddleSDI countries (1 in25),whereas the
lowest occurred in low-middle SDI countries (1 in 48). For women,
the highest odds were in low SDI countries (1 in 58) and the lowest
in low-middle SDI countries (1 in 83) (eTable 16 in the Supplement).
Globally and for high SDI countries, stomach cancer ranked fifth for
cancer incidence and third for cancer deaths in 2015 (Figures 4 and
5). Inhigh-middle,middle, low-middle, and lowSDI countries, stom-
ach cancer ranked third for incidence. For cancermortality in high-
middle,middle, and lowSDI countries, stomachcancer ranked third.
For low-middle SDI countries it ranked second for cancermortality.
ASIRsandASDRs (95%UIs) formen in2015were lowest inhigh-
incomeNorthAmerica:ASIR11.7(10.5-13.0),ASDR5.2(5.0-5.4);South
Asia:ASIR12.8(10.9-14.9),ASDR8.4(7.8-9.1);andAustralasia:ASIR15.1
(12.9-18.1), ASDR 7.0 (6.5-7.5), as summarized inWeb Tables 1 and 2.
They were the highest in high-income Asia Pacific: ASIR 90.1 (83.5-
96.9),ASDR28.5 (27.5-29.5);EastAsia:ASIR46.2 (38.8-56.5),ASDR
33.5 (31.2-36.0); and Central Asia: ASIR 34.9 (32.6-37.2), ASDR 23.6
(22.2-25.0). Forwomen, rateswere the lowest inhigh-incomeNorth
America: ASIR6.1 (5.4-6.8), ASDR2.9 (2.8-3.0); SouthAsia: ASIR6.2
(5.1-7.4),ASDR4.1 (3.7-4.5);andSouthernSub-SaharanAfrica:ASIR7.5
(6.2-8.8), ASDR 5.3 (4.6-6.2). Theywere the highest in high-income
AsiaPacific:ASIR31.5 (28.9-34.2),ASDR10.6(10.2-11.1);AndeanLatin
America:ASIR20.9(18.1-23.7),ASDR15.2(13.4-17.3);andEastAsiaASIR
18.0 (15.0-21.3), ASDR 13.3 (12.3-14.2).
Stomach cancer was highest in absolute incidence in 2015 for
men in26countriesand territoriesandwas the leadingcauseof can-
cer deaths in 11 countries (eFigures9 and 11 in the Supplement). For
women it was the leading cause of cancer deaths in 4 countries
(eFigure 12 in the Supplement).
Stomachcancerhas remained the thirdhighest cause for crude
cancer YLLs between 2005 and 2015, with a 7% decrease in abso-
lute YLLs due to stomach cancer (Figure 6). If the population age
structure and sizehad remained the same in2015 as itwas in 2005,
incidence would have dropped by 21% due to decreasing rates
(Table2).ASIRshavedroppedsubstantially since 1990at theglobal
level and for all SDI quintiles except the low SDI quintile (Figure 11).
Between2005and2015,age-standardizedDALYsforbothsexes
decreased by 27% (95% UI, −29.4% to −24.5%) globally, with the
largest decrease in high-middle SDI countries of 32% (95% UI,
−35.8% to −27.5%) (Web Table 3).
6. Liver Cancer
In 2015, there were 854 000 (95% UI, 768 000-961 000) inci-
dent cases for liver cancer globally and 810 000 (750 000-
863000) deaths. Liver cancer caused 20.6 million (19-22 million)
DALYs in 2015 with 99% coming from YLLs and 1% coming from
YLDs (eFigure 13 in the Supplement). Liver cancer was more com-
mon inmen,with 1 in 45mendeveloping liver cancer before age 79
years comparedwith 1 in 113women at the global level. The highest
odds of developing liver cancer was in middle SDI countries, with 1
in 38men and 1 in 96women developing liver cancer, whereas the
lowestoddswereseen in low-middleSDI countries,with 1 in98men
and 1 in 144 women developing liver cancer during their lifetime
(eTable 16 in theSupplement).Globally, liver cancer rankedsixth for
cancer incidence and fourth for cancer deaths in 2015, as shown in
Figures 4 and 5. In low SDI countries, it ranked fourth for cancer in-
cidence and first for cancer mortality, whereas in middle and high-
middleSDI countries it ranked fourthandsixth, respectively, for can-
cer incidence but second for cancer mortality.
ASIRs (95%UIs) (per 100000person-years)were thehighest
inmiddle SDI countries in2015 (15.6; 13.2-18.8), followedby lowSDI
countries (14.5; 11.5-17.1), high-middle (13.7; 11.6-16.3),high (11.7; 10.8-
12.7), and low-middle SDI countries (7.1; 6.2-8.3). ASDRs in 2015 for
both sexeswere the highest in the lowSDI quintile (16.6; 13.2-19.7),
Figure 10. Trends in Age-Standardized Incidence Rates for Prostate
Cancer, 1990-2015
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followed by middle SDI countries (15.8; 14.5-17.5), high-middle SDI
countries (14.5; 12.9-15.8), highSDI countries (7.9; 7.6-8.2), and low-
middle SDI countries (7.5; 6.7-8.7) (Web Tables 1 and 2).
In 2015, ASIRs and ASDRs (95% UIs) for men were the lowest
in SouthAsia: ASIR 4.7 (3.8-6.2), ASDR 5.1 (4.5-5.9); Southern Latin
America: ASIR 6.1 (5.4-7.3), ASDR 6.8 (6.2-7.5); and Tropical Latin
America:ASIR6.5 (5.5-8.2),ASDR7.4 (6.6-8.2). Theywere thehigh-
est in high-income Asia Pacific: ASIR 40.1 (34.4-48.3), ASDR 23.8
(22.5-25.2); East Asia: ASIR 36.4 (28.6-48.0), ASDR 39.3 (35.4-
44.1); and Central Sub-Saharan Africa: ASIR 24.4 (13.4-42.7), ASDR
29.4 (15.9-50.3). For women, rates were the lowest in South Asia:
ASIR 3.2 (2.4-4.5), ASDR 3.1 (2.6-3.6); Australasia: ASIR 3.6 (2.4-
6.2),ASDR2.3 (2.0-2.6); andSouthernLatinAmerica:ASIR4.0 (3.3-
5.2), ASDR 3.9 (3.5-4.3) and the highest in high-income Asia Pa-
cific: ASIR 14.2 (10.9-19.6), ASDR 7.4 (7.0-7.8); East Asia: ASIR 12.5
(9.0-18.2), ASDR 12.1 (10.3-14.1); and Western Sub-Saharan Africa:
ASIR 10.9 (7.0-15.8), ASDR 10.9 (7.0-15.8) (Web Tables 1 and 2).
Liver cancerwas themost commonlydiagnosedcancer in2015
formen in 11 countries (eFigure 9 in the Supplement) and themost
common cause of cancer deaths in 40 countries (eFigure 11 in the
Supplement). Liver cancerwas themost commonlydiagnosedcan-
cer for women in Mongolia (eFigure 10 in the Supplement) in 2015
and the leading cause of cancer deaths for women in 5 countries in
2015 (eFigure 12 in the Supplement).
Liver cancer remained the second leading cause of cancer YLLs
between 2005 and 2015 (Figure 6). Aging and population growth
were thedriversof the increase from709000(616000-782000)
cases in2005to854000(768000-961000)cases in2015,assum-
marized in Table 2. If the population age structure and size had re-
mained the same in 2015 as they were in 2005, 8% fewer cases of
liver cancerwouldhavebeendiagnosed in2015 than in2005.Glob-
ally, ASIRs slowly decreased since the late 1990s (Figure 12). This
global trend, however, masks an increase in low and high SDI coun-
tries since 1990. ASIRs have been increasing for low SDI countries
since 1990; in high SDI countries, rates decreased until the early
2000s formen and the late 2000s forwomen and then increased.
Between2005and2015, age-standardizedDALY rates for liver can-
cer decreased for both sexes by 17% (95%UI, −21.4% to −8.7%) at
Figure 12. Trends in Age-Standardized Incidence Rates for Liver Cancer, 1990-2015
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Figure 11. Trends in Age-Standardized Incidence Rates for Stomach Cancer, 1990-2015
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the global level, with the largest decrease in high-middle SDI coun-
tries of 24% (95%UI, −30.6% to −11.3%) (Web Table 3).
7. Non-Hodgkin Lymphoma
In 2015, therewere 666000 (95%UI, 584000-710000) incident
casesofNHLand231000(95%UI, 196000-244000)deaths.Non-
Hodgkin lymphomacaused6.3million(95%UI,5.4-6.6million)DALYs
in 2015, with 95% coming from YLLs and 5% from YLDs (eFigure 13
in the Supplement). One in 78men and 1 in 110women at the global
leveldevelopedNHLbetweenbirthandage79years.Thehighestodds
for developingNHLwere inhighSDI countrieswith 1 in44menand 1
in 63women developing NHL. The lowest odds occurred in low SDI
countries, with 1 in 148men and 1 in 190women developing NHL.
Globally, for both sexes combined in 2015, NHL ranked sev-
enth for cancer incidence and 11th for cancer deaths (Figures 4 and
5). The highest rank for the incidence of NHL was in low SDI coun-
tries, where it was fifth. However, NHL cancer in low SDI countries
ranked only 11th for death.
Web Tables 1 and 2 illustrate that incidence and death rates in
2015 for men were the lowest in Central Sub-Saharan Africa: ASIR
5.5 (3.4-8.9), ASDR 3.4 (2.1-5.5); Oceania: ASIR 5.8 (4.1-9.7), ASDR
3.0 (2.1-4.7); and South Asia: ASIR 6.0 (4.7-7.4), ASDR 2.9 (2.4-3.2).
They were the highest in high-income North America: ASIR 28.5
(24.2-35.0), ASDR 7.7 (6.3-8.9); Australasia: ASIR 25.3 (20.4-31.4),
ASDR6.9(5.4-8.1); andWesternEurope:ASIR20.0(15.9-23.0),ASDR
5.7 (4.3-6.3). For women, incidence rates in 2015 were the lowest
inCentralAsia:ASIR4.1 (3.4-4.6),ASDR1.5 (1.3-1.6);NorthAfricaand
Middle East: ASIR 4.4 (3.8-5.5), ASDR2.0 (1.8-2.6); and SouthAsia:
ASIR 4.4 (3.0-5.8), ASDR 2.1 (1.6-2.4). They were the highest in
high-income North America: ASIR 20.1 (17.4-26.6), ASDR 5.0 (4.6-
6.1); Australasia:ASIR 18.8 (15.5-24.1), ASDR4.7 (4.0-5.5); andWest-
ern Europe: ASIR 13.7 (11.7-15.9), ASDR 3.6 (2.9-4.0).
Non-Hodgkin lymphomaranked11thforcancerYLLs in2005and
in2015(Figure6).CasesofNHLincreasedby56%between2005and
2015 (Table 2). Population growth and population agingwould have
increased incidenceby 13%each. Rising age-specific incidence rates
with stable population size and structure between 2005 and 2015
would have increased cases by 29%. Figure 13 shows the slight in-
crease inASIRsbetween 1990and2015graphicallywith very similar
trends formen andwomen and all SDI quintiles. On the global level,
ASIRsper100000person-years(95%UI)forbothsexesforNHLhave
increased by 23% (13.1%-29.4%) between 2005 and 2015, from8.0
(7.2-8.5)to9.8(8.5-10.4),withthe largest increase inmiddleSDIcoun-
tries: 33% (11.3%-52.1%) (Web Table 1). During this timeframe, age-
standardized DALY rates (95% UIs) for both sexes increased at the
global level (1.3%increase;−8.5%to7.0%),althoughthis increasewas
notstatistically significant.Large,butnotsignificantdecreasesof6%
(−10.2% to0.1%)occurred in high SDI countries, and the largest, but
alsononsignificant, increaseoccurredinlow-middleSDIcountries(7%;
−9.4% to 17.9%) (Web Table 3).
8. Leukemia
In2015therewere606000(95%UI,573000-643000)newcases
of leukemia worldwide and 353000 (95% UI, 345000-363000)
deaths. In 2015, leukemia caused 12.0million (95%UI, 11.6-12.5mil-
lion)DALYs globally,with97%coming fromYLLs and3% fromYLDs
(eFigure 13 in theSupplement).One in87mencomparedwith 1 in 137
womendevelopedleukemiabetweenages0and79yearsattheglobal
level. Thehighestoddswereseen in thehighSDIquintile,with 1 in64
men and 1 in 116 women developing leukemia. The lowest odds
occurred in low SDI countries, with 1 in 124men and 1 in 164women
developing leukemia (eTable 16 in the Supplement).
Leukemia rankedeighth for cancer incidenceandninth for can-
cer deaths at theglobal level in 2015 (Figures4and5). Leukemia in-
cidencewasrankedhighest for low-SDIand low-middleSDIcountries
atsixthplace(leukemiawasninthandeighthforcancerdeaths in low-
SDIandlow-middleSDIcountries, respectively).Leukemiawasranked
lowest inhigh-SDI countries at 13thplace (eighth for cancerdeaths).
In 2015, ASIRs andASDRs (95%UIs) formenwere the lowest in
Eastern Sub-Saharan Africa: ASIR 6.5 (5.0-8.3), ASDR 3.8 (3.1-4.8);
South Asia: ASIR 7.0 (5.8-8.4), ASDR 4.1 (3.8-4.4); and Central Sub-
SaharanAfrica:ASIR7.2 (4.5-10.8),ASDR4.4(2.9-6.5).Theywerethe
highest for men in high-incomeNorth America: ASIR 17.1 (15.6-18.9),
ASDR 8.9 (8.5-9.4); Australasia: ASIR 16.1 (12.6-21.0), ASDR 8.8 (7.7-
10.0); andWestern Europe: ASIR 14.9 (13.7-16.5), ASDR8.6 (8.2-9.1).
Forwomen, theywerethe lowest inEasternSub-SaharanAfrica:ASIR
Figure 13. Trends in Age-Standardized Incidence Rates for Non-Hodgkin Lymphoma, 1990-2015
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4.6 (3.3-6.2),ASDR2.7 (2.1-3.5); SouthAsia:ASIR4.7 (3.8-5.8),ASDR
2.8(2.6-3.1); andWesternSub-SaharanAfrica:ASIR5.5 (4.1-7.8),ASDR
3.2 (2.5-4.3). Rateswere the highest in high-incomeNorth America:
ASIR 10.0(8.9-11.2),ASDR4.9(4.7-5.2); SoutheastAsia:ASIR9.6 (8.1-
11.2), ASDR5.6 (4.9-6.3); andNorthAfrica andMiddle East: ASIR8.9
(7.9-10.1), ASDR 5.1 (4.6-5.6) (Web Tables 1 and 2).
Leukemia led incident cases in 2015 for men in 5 countries
(eFigure 9 in the Supplement). It remained the sixth leading cause
of cancer YLLs between 2005 and 2015,with a 6% (95%UI, 2.5%-
9.9%) increase inabsoluteYLLsandan8%(95%UI,−11.1%to−4.9%)
decrease in age-standardized YLLs (Figure 6).
Between 2005 and 2015, incident cases at the global level in-
creased from 481 000 (95% UI, 456000-512 000) to 606000
(95%UI,573000-643000) (total increaseof26%(95%UI, 19.6%-
33.2%); population growth and aging were the drivers behind this
increase. Had the population growth and age-specific rates re-
mained the same as in 2005, there would be only 3% more cases
of leukemia in 2015 (Table 2). Increasing trends in ASIRs are similar
forall SDIquintilesexcept forcountries in thehigh-middleSDIgroup,
where rates have decreased since the 2000s (Figure 14).
Between2005and2015,age-standardizedDALYrates(95%UIs)
forbothsexesdecreasedby8%(−10.8%to−4.6%)attheglobal level,
withthe largestdecrease inhigh-middleSDIcountriesat 12%(−16.6%
to −8.6%), and the largest increase in low SDI countries at 9% (−3.9
to 22.8), although this increasewas not significant (Web Table 3).
9. Bladder Cancer
In 2015, there were 541 000 (95%UI, 517 000-567000) incident
cases for bladder cancer globally and 188000 (95% UI, 183000-
193000) deaths. Bladder cancer caused 3.4 million (95% UI, 3.3-
3.5million)DALYs in2015,with92%coming fromYLLsand8%from
YLDs (eFigure 13 in theSupplement).Bladdercancerwasmorecom-
mon inmen, with 1 in 59men being diagnosed before age 79 years
comparedwith 1 in239women.Theoddsofdevelopingbladdercan-
cer during a lifetimewere the highest in high-SDI countries (1 in 36
men and 1 in 165 women) and the lowest in low-SDI countries (1 in
122men and 1 in 310women) (eTable 16 in the Supplement). Glob-
ally, bladder cancer ranked ninth for cancer incidence and 13th for
cancerdeaths in2015,asshown inFigures4and5. It rankedthehigh-
est in high-SDI countries at position 8 (11th for mortality).
In 2015, ASIRs and ASDRs (95% UIs) for men were the lowest
in Oceania: ASIR 4.5 (3.6-5.8), ASDR 2.3 (1.9-2.9); Andean Latin
America: ASIR 5.8 (4.7-7.2), ASDR 2.1 (1.9-2.4); and Central Latin
America:ASIR5.9 (5.0-6.8),ASDR2.4 (2.2-2.5). Theywere thehigh-
est in high-income North America: ASIR 31.6 (28.5-35.1), ASDR 6.1
(5.8-6.4); Western Europe: ASIR 26.0 (24.1-27.9), ASDR 8.6 (8.1-
9.1); and Central Europe: ASIR 24.1 (21.9-26.6), ASDR 9.4 (8.6-10.1).
Forwomen, incidence rates in2015were the lowest inOceania:ASIR
2.1 (1.6-2.8), ASDR 1.2 (0.9-1.5); Southeast Asia: ASIR 2.2 (1.8-2.7),
ASDR 1.2 (1.0-1.4); and Andean Latin America: ASIR 2.3 (1.8-2.8),
ASDR 1.1 (0.9-1.2). They were the highest in high-income North
America:ASIR7.7 (6.7-8.8),ASDR1.8 (1.7-1.9);WesternEurope:ASIR
5.7 (5.2-6.3), ASDR 2.0 (1.9-2.2); and Southern Sub-Saharan Africa:
ASIR 5.1 (4.0-6.6), ASDR 2.4 (2.0-2.9) (Web Tables 1 and 2).
Bladder cancer was the most commonly diagnosed cancer in
2015 for men in Egypt (eFigure 9 in the Supplement). Globally, it
dropped from the 17th to the 18th leading cause of cancer YLLs be-
tween2005and2015 (Figure6).Agingandpopulationgrowthwere
the drivers of the increase: from 413 000 (95% UI, 403 000-
424000) cases in 2005 to 541 000 (95% UI, 517 000-567000)
cases in 2015 (Table 2). If population age structure and size had re-
mained the same in 2015 as they were in 2005, bladder cancer in-
cidencewould have been stable. However, population growth and
aging led to a 31% increase in incident cases. Worldwide, as well as
inhighandhigh-middleSDIcountries,ASIRspeaked in the late 1990s
in both sexes followed by a slow decrease (Figure 15). Rates in-
creased in the low and low-middle quintiles. Between 2005 and
2015,age-standardizedDALYrates (95%UIs) forbothsexes forblad-
der cancer decreased by 9% (−11.5% to −6.2%) at the global level,
with the largest decrease in high-middle SDI countries by 13%
(−17.0% to −9.7%), and the largest (although nonsignificant) in-
crease in low SDI countries of 3% (−8.8% to 18.2%) (Web Table 3).
10. Cervical Cancer
In 2015, 526000 (95%UI, 483000-571 000) women developed
cervical cancer worldwide, and it caused 239 000 (95% UI,
Figure 14. Trends in Age-Standardized Incidence Rates for Leukemia, 1990-2015
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225000-252000) deaths (Table 1). Cervical cancer caused 7 mil-
lion (95% UI, 6.5-7.4 million) DALYs, with 96% coming from YLLs
and 4% from YLDs (eFigure 13 in the Supplement).
One in68womendevelopedcervical cancerbetweenbirthand
age 79 years at the global level (eTable 16 in the Supplement). The
oddswere the highest in low SDI countries, with 1 in 24womende-
velopingcervical cancer, and the lowest inhighSDI countries,where
1 in 115 women developed cervical cancer during a lifetime.
In 2015, ASIRs andASDRs per 100000person-years (95%UIs)
for womenwere the lowest in Australasia: ASIR 5.6 (4.8-6.5), ASDR
2.4 (2.2-2.7); North Africa andMiddle East: ASIR 7.5 (5.8-9.3), ASDR
3.3(2.8-3.9);andhigh-incomeNorthAmerica:ASIR7.6(6.7-8.6),ASDR
2.9 (2.8-3.1); and thehighest inCentral Sub-SaharanAfrica:ASIR47.4
(25.9-82.4),ASDR24.7(13.8-39.9);SouthernSub-SaharanAfrica:ASIR
46.8(35.0-62.3),ASDR27.0(21.7-34.0);andOceania:ASIR42.3(22.7-
70.2), ASDR 15.6 (9.2-23.1) (Web Tables 1 and 2).
In2015, cervical cancerwas themostcommonlydiagnosedcan-
cer for women in 11 countries (eFigure 10 in the Supplement) and
the most common cause of cancer deaths for women in 50 coun-
tries (eFigure 12 in the Supplement).
Cervical cancer dropped from the ninth to the tenth leading
cause for cancer YLLs between 2005 and 2015, with a 19% (95%
UI,−25.8%to−12.0%)decrease inage-standardizedYLLs (Figure6).
Total incidencewouldhavedecreasedby26%if thepopulation size
and age structure had remained the same as in 2005 due to de-
creasing incidence rates (Table 2). ASIRs decreased globally for all
SDI quintiles (Figure 16). Between 2005 and 2015, age-
standardized DALYs decreased globally in women by 19% (95%
UI, −23.9% to −12.2%) with rates decreasing by 17% to 23% in
low-middle, middle, high-middle, and high SDI countries, but only
by 13% (95% UI, −32.6% to 10.0%) in low SDI countries (Web
Table 3).
Trends in Incidence for Less Common Cancers
Incidence (95%UI) for both sexes increased substantially between
2005 and 2015 for certain cancers, as summarized in Table 2. Thy-
roid cancer cases almost doubled between 2005 and 2015, from
168 000 (160 000-178 000) to 334 000 (310 000-353 000)
cases. Seventy-one percent of this change can be explained by an
increase in age-specific incidence rates (Table 2). At the same time,
the age-standardized YLL rate for thyroid cancer decreased signifi-
cantlyby7%(95%UI,−15.0%to−2.3%) (Figure6).Melanomacases
increased from 225000 (187000-289000) in 2005 to 352000
(282000-445000) in 2015, a 56% (95% UI, 48.0%-63.9%) in-
crease. Twenty-eight percent of the change can be explained by an
increase in the age-specific incidence rates (Table 2). Kidney can-
cer cases increasedby53%(95%UI, 45.7%-59.7%)between2005
and 2015 (from 279 000 (271 000-288 000) to 425 000
(405000-447000), with age-specific rates contributing 23% to
this total increase. Mesothelioma has increased from 26 000
(25000-27000)to37000(35000-29000)casesbetween2005
and 2015, a 40% (33.4%-47.0%) increase, of which 9% can be at-
tributed to a rise in age-specific rates.
Discussion
Between2005and2015, theproportionofdeaths fromnoncommu-
nicablediseases (NCDs) increased from65%in2005to71% in2015
at theglobal level.1 Fourteenpercentof all deaths in2005weredue
tocancer,which increasedto16%in2015.1SevenpercentofallDALYs
Figure 16. Trends in Age-Standardized Incidence Rates for Cervical
Cancer, 1990-2015
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Figure 15. Trends in Age-Standardized Incidence Rates for Bladder Cancer, 1990-2015
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in2005wereduetocancer,which increasedto9%in2015.19Deaths
due to communicable,maternal, neonatal, andnutritional diseases
decreased from 26% in 2005 to 20% in 2015.1 These numbers are
evidence thatNCDsmaybe abarrier to future development.20 The
international health community has responded to this threat, with
majormilestonesbeing the2011UnitedNationspolitical declaration
onNCDpreventionandcontrol,21 theWorldHealthOrganizationGlob-
alActionPlan for thePreventionandControl ofNCDs2013-2020,22
andthe integrationofNCDs in theSustainableDevelopmentGoals.11
The GBD 2015 study identifies some progress in meeting the
targetsof theSustainableDevelopmentGoals.23Between2005and
2015,manycountriesexperiencedadecrease incancermortalityde-
spite increasing incidencerates.Countrieswith increasingcancermor-
tality rates were dominantly in Sub-Saharan Africa where, with few
exceptions, the complex health care infrastructure required to treat
cancer is generally lacking.24Efforts areongoing toexpand theexist-
ingresources intheregiontoallowfor improvedcancercare.25-28Can-
cer prevention efforts may, however, be as important as delivery of
care, given the profile of cancer in lowSDI countrieswhere the top 3
leading causes of cancer mortality (liver cancer, cervical cancer, and
stomach cancer) are largely preventable.
PreventionandtreatmentofchronichepatitisBandC,whichac-
count for themajority of liver cancer deaths, would reduce the inci-
dence and mortality of liver cancer.29 The World Health Organiza-
tionhasadoptedaglobalhealthsector strategyonviralhepatitis that
featuresa2030targetofa65%reductioninmortalityrelatedtohepa-
titisBandC.This is tobeachievedbyreducing theoccurrenceofnew
chronic hepatitis B andC infectionsby90%through increasednew-
born hepatitis B immunization coverage, blood and injection safety,
harm reduction, and by an80% treatment rate for chronic hepatitis
BandC.30Our results showthat trends for liver cancer incidencedif-
feramongtheSDIquintiles.ASIRshavebeendecreasingat theglobal
level and for most SDI quintiles since at least 2000. However, rates
for high SDI countries have increased since 1990, and rates for low
SDI countries increased in themost recent observations (from2010
to2015).Thesefindingsareconsistentwithobservationsinsomehigh-
incomecountries,whereobesity,diabetes,andhepatitisCarethought
to bemajor contributors to rising incidence rates.31,32
Humanpapillomavirus vaccination is universally recommended
by health authorities and is expected to reduce cervical cancer inci-
denceover thenextdecades ifvaccinationuptake issuccessful. In the
meantime, screenand treat approaches thathavebeenshownto re-
duce cervical cancer mortality in high-income countries should be
implemented inregionswithahighburdenofcervicalcancer.33-35The
stark inequitybetweenhighSDIcountrieswherecervicalcancer is the
18th leading cause of cancer deaths compared with low SDI coun-
tries where it ranks second (Figure 5) is widely recognized by the in-
ternational community; anemergingpolitical commitment to reduc-
ingthisgapwillhopefully translate intoadecreasedburdenofcervical
cancer in themost affected countries.36Our results show that prog-
ress in reducing cervical cancer burden was the slowest in low SDI
countries where the decrease in ASIRs and ASDRswas the lowest; a
12%decrease in ASIR occurred for countries at lowSDI compared to
a greater than 14%decrease in all other SDI quintiles, and a 14%de-
crease in ASDR in low SDI compared to the other SDI quintiles, with
decreases in ASDR of greater than 16%.
Stomachcancer rateshavebeendecliningglobally fordecades.37
However, our results demonstrate that this trend has not been uni-
form among the SDI quintiles. ASIRs in the lowest SDI quintile in-
creased throughout theGBDstudy timeframe (1990 to2015). In the
highest SDI quintile, rates declined until 2010 but have since in-
creased.Onepossibleexplanationistheincreasingtrendofgastriccan-
cer of the cardia in high-income countries owing to risk factors such
asobesity, although themechanismexplaining this association isnot
fully understood.37-39 Treatment for Helicobacter pylori infection,
whichcausesabout78%ofall stomachcancers, reducesgastric can-
cer incidence, and the International Agency for Research on Cancer
(IARC) recommends that countries investigatewhether population-
basedscreeningandtreatmentprogramsforHpyloriareindicated.40,41
Despite this recommendation, few countries with high incidence of
stomach cancer have implemented populationwide screening pro-
grams. Although studies have shown reductions in stomach cancer
mortality in screened populations, the target group, onset, andmo-
dality of screening programs remain controversial.37,42-46
Prevention and treatment of carcinogenic infections that lead
to theseobservedcancerpatterns in lowSDI countrieshave thepo-
tential to decrease future cancer burden as well as reducing asso-
ciated diseases like cirrhosis in endemic areas.47 In addition, limit-
ing transmission can lead to prevention efforts that are sustained
beyond 1 generation.10
Thedominanceof infection-relatedcancers in lowSDI countries
is an exceptional pattern compared with the leading causes of can-
cer deaths for countries in higher SDI quintiles, where TBL, colorec-
tal, stomach, liver, and breast cancer lead the rankings. The impor-
tance of tobacco control as a crucial cancer control strategy should
thereforenotbeunderestimated,especiallysincetobaccocontrolhas
healthbenefitsreachingfarbeyondcancerprevention.48Effectivepri-
mary and secondary prevention strategies are available for colorec-
tal cancer with many risk factors being attributed to “Western
lifestyles.”49Increasedphysicalexercise,avoidanceofprocessedmeat,
alcohol, and tobacco, as well as aspirin use have all been associated
withreducedcolorectal cancer incidence.49-52Multiplemodalities for
colorectal screeningareknowntoreducecolorectalmortality inhigh-
incomecountries.53,54Meansof implementation inotherhealthcare
settings iscurrentlybeing investigated.55Primarypreventionofbreast
cancer, which is the leading cause of cancer incidence, death, and
DALYs in women, should be emphasized. However, even in the set-
tingofpopulationwideprimarypreventionefforts, it isestimatedthat
onlybetween20%and50%ofbreastcancercanbeprevented.48,56
Therefore, breast cancer control strategies must also focus on early
detection in addition to effective treatment. Early detection strate-
gies can range from improving breast cancer awareness and clinical
breast examination in basic resource settings to mammography
screening.57Clearly, cancercontrol strategies focusedonearlydetec-
tion should also target access to the full spectrum of care including
surgical, medical, and radiation oncology; affordable chemothera-
peutics and supportive drugs; and survivorship support and pallia-
tive and hospice care.58 This is imperative not only for breast cancer
but for comprehensive cancer care in general.
Thevariation in the leading causesof cancer incidence andmor-
tality between countries documented in the GBD study are remark-
able. The largest ranges in rankings for cancer mortality were found
in cervical cancer, acute lymphoid leukemia, and nasopharynx can-
cer followed by esophageal, lip and oral cavity, gallbladder and bili-
ary tract cancer, and melanoma (eFigure 8 in the Supplement). For
cancer incidence, the largest divergence was seen in esophageal
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cancer, cervical cancer, melanoma, acute lymphoid leukemia, kid-
ney, larynx, and gallbladder and biliary tract cancer (eFigure 7 in the
Supplement).Formostof thesecancers, theobservedpatterncanbe
explained by known risk factors or by access to care. In acute lym-
phoid leukemia, forexample, it iswell knownthat thesurvival rate for
childrendiffers substantially between countries fromaround 15%to
over 90%, suggestive of disparities in treatment.59 For nasophar-
ynx cancer it is also well known that incidence differs drastically be-
tweenpopulations; thiscan inpartbeexplainedbyearly infectionwith
Epstein-Barrvirusaswell asbyahigh intakeofsalt-preservedfood.60
Melanoma is a muchmore common in populations with lighter skin
types.61 Esophageal cancer is a similar exampleofwidelydiffering in-
cidenceratesattributabletorisk factorprofiles.Riskfactors foresoph-
ageal cancervarydependingonthehistologiccharacteristicsofsqua-
mouscell carcinomavsadenocarcinoma.Forexample, it ispostulated
that the diverse incidence of esophageal squamous cell carcinoma,
the dominant histologic type in high-endemic areas, is driven by
chroniccell damage fromrisk factors like smoking, alcohol consump-
tion, heat damage, and nutritional deficiency.62,63 Risk factors for
esophageal adenocarcinoma,which is increasing in traditionally low-
endemic areas, include a high bodymass index, smoking, reflux dis-
ease, and a diet low in fruits and vegetables.64,65
A detailed analysis of the reasons behind the observed varia-
tion in cancer burden goes beyond the scope of this analysis. How-
ever, thecitedexamples showthat thedescriptiveepidemiologyap-
proachof theGBDstudycan identifypatternsof cancerburden that
can be hypothesis generating. This is especially true when cancer
burden is analyzed in conjunctionwith nonmalignant diseases that
might share similar risk factors—a potential provided by the com-
prehensive nature of the GBD approach.
Limitations
AsinpriorGBDstudies,ourestimatesdependonthequalityandquan-
tity of thedata sources available to inform theestimates. Becauseof
the lag time for data reporting, estimates for 2015 aremainly based
ondataandtrendsfromrecentyears.Formanycountries,datasources
for informing cancer burden estimation are still sparse, and theGBD
estimates rely heavily on covariate selection in the models and re-
gionalpatterns.Onlyanestimated38%ofdeathsworldwidewerereg-
istered in 2012.66Alternativedata sources for cancermortality, such
as verbal autopsy, are substantially less reliable.67 To overcome the
limitation from lack of data sources, the GBD study includes cancer
incidencedata fromregistries in themortalityestimation.Cancer reg-
istration has a long tradition in many countries. However, in regions
where the burden of cancer is expected to grow significantly due to
anticipatedpopulationgrowthandaging,cancer registriesoftenonly
cover a small fraction of the population, are of low quality, or do not
exist.68Comparedwithalmostcompletecoverageof thepopulation
with high-quality cancer registration in Nordic countries or North
America, less than 10%of thepopulation inSouthAmerica,Asia, and
Africa are covered by high-quality cancer registries.68 With techno-
logical innovation, including an improved ability to identify and link
different typesofdata sources, cancer surveillancewill hopefullybe-
come a routine component of every health care system. Endeavors
like theGlobal Initiative forCancerRegistryDevelopment (http://gicr
.iarc.fr) play amajor role in this task.
Cancermortalityestimatesarepredominantlybasedonvital reg-
istrationdata, cancer registrydata, andtoamuch lesserextentother
data sources. If a large proportion of deaths are miscoded, the re-
distributionof theseso-calledgarbagecodescansubstantially affect
mortalityestimates.SinceGBDcancer incidenceestimatesarebased
on mortality estimates, garbage code redistribution directly af-
fects cancer incidence. Misclassification of metastatic sites as pri-
mary cancer sites (eg, liver, lung, brain) is another source of poten-
tial bias, especially in locations with limited diagnostic resources.
Changes in codingpractices or coding systemsmay also have anef-
fect, even though mapping to the GBD causes list includes adjust-
ments to account for different coding systems.69
Cervical anduterinecancer incidence ratesarepotentiallyover-
estimated in the GBD in locations where hysterectomies are com-
mon, since rates are calculated without adjustments for the popu-
lation at risk.
For GBD 2015, we have updated theMI (mortality to incidence)
ratios andusedout-of-sample validation of a set of potentialmodels
to choose the most appropriate MI model. However, in young age
groups with sparse data, and in areas where no matching mortality
and incidencedataexist (which is the case formost countries in Sub-
SaharanAfrica), theMImodel is based on the combination of trends
for older age groups aswell as covariate selection.
Theadditionof the leukemia subtypes for theGBD2015 study is
anecessarystep;aggregating“leukemia” intoasingleentity isappro-
priate from neither a public health nor a clinical perspective. How-
ever, when interpreting the results, it is important to recognize that
thosedata sources for theMI ratios thatdetermine incidence for leu-
kemia subtypes aremostly fromhigh-incomecountries. Another ca-
veat is that leukemiasubtypesarescaledtosumtothe leukemia“par-
ent” cause, which can lead to incidence estimates for leukemia
subtypes that are different than what would be expected based on
theMIratioalone.Changes inclassificationof leukemiasubtypesover
time can also have an effect on the GBD estimates. With the wider
availability of cancer registry data, including childhood cancer regis-
tries, it is expected that estimates will continue to be adjusted in
future iterations of the GBD.
Conclusions
Despite significant reductions in cancer mortality in many coun-
tries, cancer poses abarrier to futuredevelopment. Incidence is ex-
pected to increase, straining resources even in countries with ad-
vanced health care systems. An expanding arsenal of cancer
prevention and treatment interventions, together with a political
commitment to address NCDs, offers hope that this threat can be
controlled. The GBD study enables timely tracking of progress to-
ward defined targets.23 Sincemost cancer prevention efforts have
amuchbroader impact than just reducingcancer incidence, theabil-
ity of the GBD to put single diseases into the perspective of popu-
lation health is unique and of the utmost importance.
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